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Reocclusionafter successfulcoronary reperfusion occurs
in 15 to 35% of patients receiving thrombolytic therapy
for acute myocardial infarction. The present study was
designed to simulate the clinical situation of reocclusion
and determine whether verapamil might be effective in
reducing myocardial necrosis and preserving high en-
ergy phosphates in this setting. Pentobarbital-anesthe-
tized, open chest dogs underwent occlusion of the left
anterior descending coronary artery for 2 hours followed
by 1 hour of reperfusion and a further 4 hours of coro-
nary artery occlusion. Treatment with verapamll (in-
travenous bolus dose of 0.2 mg/kg body weight followed
by infusion of 0.56 ± 0.14 mg/kg per h) was begun 1
hour after occlusion and infusion was continued for the
remainder of the experiment. The dose of verapamil was
adjusted to lower mean arterial pressure to approxi-
mately 90 mm Hg. The area at risk was determined by
intraatrial injection of monastral blue dye and the area
of necrosis was assessed by triphenyltetrazolium chloride
Early reperfusion in dogs subjected to acute myocardial
ischemia shows salvage of ischemic myocardium, an even-
tual reduction of myocardial dysfunction and improvement
in myocardial high energy phosphate content (1-3). With
the advent of thrombolytic therapy and emergency percu-
taneous transluminal coronary angioplasty, as well as the
combination of these therapies, it is now possible to institute
reperfusion within a few hours from the onset of ischemia
in many patients with acute myocardial infarction (4). Clin-
ical trials with thrombolytic agents have shown a reperfusion
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staining. In vivo myocardial needle biopsy for deter-
mination of adenosine triphosphate and creatine phos-
phate was performed at the end of the experiment.
The area of the left ventricle at risk was similar in
both groups (control [n = 8], 20.2 ± 1.6% versus ve-
rapamil-treated [n = 9], 23.1 ± 2.9%; p = NS). The
area of necrosis expressed as a percent of the area at
risk was reduced in the verapamil-treated group com-
pared with the control group (43.3 ± 5.0% versus
63.1 ± 6.8%, p < 0.05). At the termination of the
experiment, the adenosine triphosphate and creatine
phosphate were significantly higher in both the epicar-
dium and endocardium of the ischemic area in the ve-
rapamil-treated group compared with the control group.
In conclusion, verapamil reduced or at least delayed
the necrosis in an experimental model of reocclusion
after an initial period of reperfusion and was associated
with a preservation of high energy phosphate content.
(J Am Coli Cardiol1986;&1l69-74)
success rate ranging from 60 to 80% (5-9). However,
thrombolytic therapy simply lyses the clot and does not
affect the other factors that lead to occlusion of a coronary
artery. Consequently, reoccJusion of a coronary artery opened
with a thrombolytic agent or by means of coronary angio-
plasty, or both, occurs in 15 to 35% of patients (10-12),
and can negate the beneficial effects of the initial reperfusion.
The aim of the present study was to determine whether
verapamil, a calcium charinel blocking agent known to sal-
vage ischemic myocardium, would be efficacious in an ex-
periment in which reocclusion occurs after an initial period
of ischemia and reperfusion.
Methods
Surgical procedures. Mongrel dogs of either sex,
weighing between 17 and 30 kg, were anesthetized with
sodium pentobarbital (30 mglkg body weight intrave-
nously), intubated and artifically ventilated with room air
using a Harvard respiratory pump. Additional doses of 5 to
0735-1097/86/$3.50
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10 rng/kg of sodium pentobarbital were administered intra-
venously as required to maintain adequate anesthesia
throughout the experiment. Cannulas were positioned in the
left carotid artery for monitoring arterial pressure and for
withdrawal of reference blood samples to determine regional
myocardial blood flow, and in the left jugular vein for
administration of fluids and drugs . A thoracotomy was per-
formed in the fifth left intercostal space , a pericardial cradle
was constructed and the left anterior descending coronary
artery was isolated proximal to the first major diagonal branch.
A third cannula was placed into the left atrium for admin-
istration of radioactive microspheres to determine regional
myocardial blood flow.
Experimental protocol. After obtaining baseline mea-
surements of heart rate and arterial pressure on a Gould
multi-channel pen recorder, a bolus of lidocaine (1.5 mg/kg
intravenously) was injected and the left anterior descending
coronary artery was occluded for 2 hours using an atraumatic
Schwartz vascular clamp . A total of 81 dogs were entered
into the study , of which 29 died of ventricular fibrillation
within 30 minutes of coronary artery occlusion; the re-
maining 52 dogs were randomized I hour after occlusion .
Of the randomized dogs, 17 were randomized to the protocol
described herein (8 in the control group and 9 in the ve-
rapamil treated group) and 35 were randomized to a second
study group (Campbell et aI., unpublished data, 1986). The
aim of the verapamil treatment was to reduce mean arterial
pressure (electronically determined) to 90 mm Hg. This was
achieved by administering an intravenous bolus of 0.2 mg/kg
verapamil followed by a continuous infusion of verapamil
utilizing a dose adjusted to produce the desired effect ; the
verapamil (or an equivalent volume of saline solution) was
infused until the termination of the experiment. After 2 hours
of coronary occlusion, reperfusion was instituted by abrupt
removal of the Schwartz clamp . After I hour of reperfusion
the left anterior descending coronary artery was reoccluded
for 4 hours. At the end of the second occlusion, the in vivo
area at risk was determined by injecting monastral blue dye
(I mllkg) into the left atrium .
The dogs were killed with an intraatrial injection of po-
tassium chloride (40 to 60 mEq) and the heart was excised.
The atria and right ventricle were removed and the left
ventricle was sectioned transversely from apex to base into
4 to 5 mm sections. The area of tissue unstained by mon-
astral blue dye, representing the area at risk as previously
described (13) , was traced onto acetate sheets. The sections
were then incubated in triphenyltetrazolium chloride at 35°C
for 10 minutes and the area unstained by triphenyltetrazo-
liurn chloride, representing the area of necrosis , was traced
onto acetate sheets. The size of the area at risk and area of
necrosis was determined by the "cut and weigh" technique
as previously described (13,14) . Validation of the triphen-
yltetrazolium chloride technique to quantify the area of ne-
crosis has been previously reported (15,16).
Regional myocardial blood flow determination. Sam-
ples of myocardium weighing approximately 1 g were cut
from the epicardial, midmyocardial and endocardial regions
in the centers of the necrotic and non-necrotic areas for
determination of regional myocardial blood flow. The latter
was determined before occlusion (before lidocaine) , at 30
minutes after the first occlusion , and 30 minutes after the
onset of reperfusion by the injection of 2.0 x 106 radio-
active (scandium-46, tin-113 , cesium-141) microspheres
(10 ± 1 ~m diameter) while an arterial reference blood
sample was withdrawn at 15.3 mllmin using a Harvard
withdrawal pump. Regional myocardial blood flow (RMBF)
in the tissue sample (mllmin per g) was calculated using the
formula: RMBF = Cs x (CB/CR), where Cs = counts in
myocardial tissue sample corrected per gram; CB = rate
of withdrawal of the reference blood sample and CR =
total counts in reference blood sample (17).
Myocardial biopsy procedure. At the end of the ex-
periment, that is, after 4 hours of reocclusion, and before
the injection of monastral blue dye, single in vivo myo-
cardial biopsy samples were obtained from the centers of
the ischemic and nonischemic areas using a disposable bi-
opsy needle (Tru-Cut, Travenol) as previously described
(18,19). The biopsy samples were frozen within 5 seconds
by immersion in liquid Freon 12 and stored at - 65°C until
analysis. Adenosine triphosphate and creatine phosphate were
determined fluorimetrically (20) .
The animals used in this study were maintained in ac-
cordance with guidelines of the Committee on Animals of
the Harvard Medical School and those prepared by the Com-
mittee on Care and Use of Laboratory Animals of the In-
stitute of Laboratory Animal Resources, National Research
Council (DHEW PublicationNo. [NIH] 78-23, revised 1978).
Statistical analysis. Comparisons between the two groups
were performed using Student's t tests, with the Bonferroni
procedure where applicable for multiple hemodynamic mea-
surements (21). A probability (p) level of less than 0.05
was considered statistically significant. All values are ex-
pressed as mean ± SEM.
Results
Hemodynamics (Fig. 1). Both groups maintained a sim-
ilar mean arterial pressure for the first hour after occlusion
of the left anterior descending coronary artery. At I hour
after occlusion, the verapamil treatment commenced and
the nine dogs receiving verapamil exhibited a mean arterial
pressure of 90 mm Hg or less, whereas the eight dogs in
the control (saline-treated) group maintained a stable mean
arterial pressure throughout the 7 hour experimental period
(Fig. IA) . The maintenance dose of verapamil required to
maintain the mean arterial pressure at approximately 90 mm
Hg was 0.56 ± 0.14 mg/kg per h, after a bolus injection
of 0 .2 mg/kg. The control group maintained a steady heart
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Figure I. Mean arterial pressure (A) and heart rate (B) are shown
before occlusion (0 hour) and at hourly intervals throughout the 7
hour observation period . Control animals (n = 8) are shown as
filled circles and verapamil-treated animals (n = 9) as open squares .
*p < 0.05 ; **p < 0.0 I; ***p < 0 .00 I . control versus verapamil-
treated group.
rate throughout the experimental period . In contrast, at I
hour after occlusion in the treated group , the heart rate began
to fall and was significa ntly lower than that of the control
group at 2, 4 and 5 hours after occlusion (Fig . l B).
Area at risk and area of necrosis. The area of myo-
cardium at risk because of the occlu sion of the left anterior
descending coronary artery was similar in both the control
and verapamil-treated groups (23 .1 ± 1.9 versus 20.2 :±:
1.4% of the left ventricle; p = NS) . Verapamil treatment
significantly reduced the area of necrosis expressed as a
percent of the left ventricle, from 14,6 ± 1.9% in the contro l
Discussion
In this study, a total of 6 hours of left anterior descending
coronary artery occlusion, which was interrupted by I hour
of reperfusion, resulted in an area at risk that proceeded to
a level of necros is averaging 63% , which is lower than that
group to 8.7 ± 1.2% in the verapamil -treated group (p <
0.05). When the area of necrosis was expressed as a percent
of the area at risk, the treated dogs exhibited a significant
reduction compared with control dogs (63.3 ± 6.8 versus
43 .3 ± 5.0%, P < 0.05).
High energy phosphate concentration (Table 1). In
vivo myocardial biopsy specimens from ischemic and non-
ischemic areas were taken at the end of the experimental
period . There were no differences between the verapamil
and control groups in the concentration of adenosine tri-
phosphate or creatine phosphate in the epicardium or en-
docardium of the nonischemic area , In contrast, in the is-
chemic area the concentrations of adenosine triphosphate
and creatine phosphate in the epicardium and endocardium
were significan tly higher in the verapamil group than in the
control group.
Regional myocardial blood flow (Table 2). The re-
gional myocardial blood flow of the area supplied by the
left anterior descending coronary artery was markedly and
similarly reduced after coronary occlu sion in the epicar-
dium , midmyocardium and endocardium in the control and
treated groups . The regional myocardial blood flow in the
nonischemic area remained stable during the ischemic phase.
There was a statistically insignifica nt trend for the regional
myocardial blood flow measured 30 minutes after reperfu-
sion to be higher in the verapamil-treated group than in the
control group in all layers of the myocardium , both in nor-
mal and in previously ischemic areas.
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Table I. Intramyocardial Adenosine Triphosphate and Creatine Phosphate Concentrations
(nmol/mg card iac prote in) in the Epicardium and Endocardium of Ischemic and
Nonischemic Myocardium
Ischemic Nonischemic
Epicardium Endocard ium Epicardium Endocardium
ATP
Control 12.03 :t 2.59 3.68 :t 0 .72 33. 12 ::':: 2.03 33.63 ::':: 1.53
(n = 8)
Verapami l 22.08 :t 2.39 8.4 1 :t 0.67 31.96 ± 1.03 35.40 ::':: 1.97
(n = 9)
P Value < 0.05 < 0.01 NS NS
CP
Control 37.88 ± 8.40 15.80 ± 3.18 54.42 ± 4.83 53. 10 :t 3.57
(n = 8)
Verapamil 64.47 ± 6.09 43.53 ± 7.19 62.06 ± 2.37 58.21 :t 2.63
(n = 9)
p Value < 0.05 < 0.00 1 NS NS
ATP = adenosine triphosphate; CP = creatine phosphate; NS = not significant.
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Table 2. Regional Myocardial Blood Flow (mllmin per g) Determined Before Occlusion (Pre), 30 Minutes After Occlusion (Post)
and 30 Minutes After reperfusion (Rep) in Control (n = 8) and Verapamil-Treated (n = 9) Groups
Ischemic Nonischemic
Control Verapamil p Value Control Verapamil p Value
Pre
Epi 1.20 ± 0.09 1.1\ ± 0.19 NS 1.10 ± 0.09 0.94 ± 0.19 NS
Mid 1.27 ± 0.1\ 1.I1±0.14 NS 1.36 ± 0.09 1.17 ± 0.18 NS
Endo 1.23 ± 0.10 1.08 ± 0.13 NS 1.44 ± 0.13 1.33 ± 0.14 NS
Post
Epi 0.28 ± 0.09 0.33 ± 0.08 NS 1.04 ± 0.11 0.85 ± 0.10 NS
Mid 0.1\ ± 0.04 0.13 ± 0.05 NS 1.32 ± 0.13 1.27 ± 0.12 NS
Endo 0.05 ± 0.02 0.05 ± 0.03 NS 1.43 ± 0.15 1.43 ± 0.09 NS
Rep
Epi 1.42 ± 0.18 1.55 ± 0.40 NS 1.02 ± 0.20 1.73 ± 0.77 NS
Mid 1.31 ± 0.20 1.57 ± 0.49 NS 1.08 ± 0.09 1.60 ± 0.59 NS
Endo 1.38 ± 0.21 2.23 ± 0.45 NS 1.12 ± 0.16 1.26 ± 0.31 NS
Endo = endocardium; Epi = epicardium; Mid = midmyocardium; NS = not significant.
in models of permanent coronary occlusion of 6 hours'
duration (18). The effect of the verapamil treatment was to
reduce or at least delay the progress of the wave front of
necrosis (22), to produce an area at risk that proceeded to
necrosis of 43.3 ± 5.0%. Associated with the reduction in
infarct size, verapamil preserved high energy phosphates in
the area at risk. These phenomena occurred while arterial
blood pressure was intentionally lowered.
High energy phosphates. During the initial phase of
ischemia, before the development of irreversible damage
and cell death, the stores of adenosine triphosphate and
creatine phosphate rapidly become depleted (19). Adenosine
triphosphate is metabolized to adenosine, inosine and hy-
poxanthine. Because the cell membrane is permeable to
these metabolites, they are washed out during reperfusion.
The repletion of adenosine triphosphate must occur by de
novo synthesis of purines, a slow process. In the present
study there was preservation of the subepicardial rim of
tissue which had been subjected to ischemia but did not
progress to necrosis, both in the control and in the vera-
pamil-treated group. The calcium channel blocker not only
reduced the extent of necrosis but also protected the reper-
fused, salvaged myocardium from further reduction in high
energy phosphate content.
Mechanisms of action. The mechanisms of action of
calcium channel blockers are complex and involve the an-
tagonism of transmembrane calcium fluxes, vasodilation of
coronary and peripheral blood vessels and reductions in
cardiac contractility and automaticity (23,24). Because ve-
rapamil treatment lowered heart rate and arterial pressure,
it is probable that it reduced global oxygen demand, which
may have contributed to the reduction in infarct size. Other
interventions that reduce global oxygen demand have been
shown to reduce infarct size (25). However, because the
contractility of the myocardium is drastically reduced during
ischemia (26), the relation between global oxygen require-
ments and the oxygen requirements of the ischemic myo-
cardium is unclear. It is also uncertain whether calcium
channel blockers have any effect on the collateral circula-
tion; some studies show an increase (27), whereas others
show no effect (28). Verapamil can also inhibit platelet
aggregation (29) and possibly thrombus formation in the
coronary vasculature, thereby reducing the obstruction to
coronary blood flow and the degree of ischemia. Finally,
verapamil may have had a direct effect on calcium flux
across the sarcolemmal membrane or within intracellular
compartments which could have resulted in a protective
action on reversibly injured myocytes.
The time at which verapamil began its beneficial effect
in this study is unclear. It may have commenced during the
first hour of its administration, that is, during the second
hour of the initial occlusion, because verapamil has been
shown to be protective when administered during ischemia
(13,30). It seems unlikely that the major protective effect
occurred during reperfusion, because in other experiments
in our laboratory, it was observed that intracoronary vera-
pamil had no effect on infarct size when its administration
was begun at the time of reperfusion 3 hours after coronary
occlusion (13). One major effect of reperfusion in the pres-
ent experiments may have been to transport verapamil into
the previously ischemic area. Therefore, because verapamil
had been delivered to the ischemic area during the reper-
fusion phase, it is possible that its major protective effect
occurred during the second occlusion.
Comparison with previous studies. The limitation of
infarct size in dogs by verapamil has been previously re-
ported (30-32). These studies have varied both the duration
of coronary artery occlusion (from 40 minutes to 24 hours)
and the start of verapamil treatment (from 15 minutes before
occlusion up to 1 hour after occlusion). Reimer and Jennings
(32) reported that infusion of verapamil beginning before
occlusion and lasting for the duration of the occlusion re-
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duced infarct size in animals subjected to 40 minutes of
occlusion plus 4 days of reperfusion; however, no such
protection was observed when the verapamil infusion was
begun 15 minutes after occlusion in a protocol of 3 hours
of occlusion plus 4 days of reperfusion. The discrepancy
between these two protocols has two possible explanations:
1) protection occurred when verapamil was given before
occlusion, thus allowing verapamil into the area soon to
become ischemic, or 2) verapamil delayed the onset of ne-
crosis but not the ultimate infarct size. In our present study,
although verapamil treatment began 1 hour after occlusion,
at 2 hours after occlusion reperfusion was instituted, thereby
allowing verapamil free access to the previously ischemic
area before the second occlusion.
In summary, the protocol used in this study was designed
to simulate the clinical situation in which a coronary artery
is reoccluded after an initial phase of severe myocardial
ischemia followed by successful reperfusion. Infusion of
verapamil, at a dose that causes only modest lowering of
arterial pressure, commencing during the initial ischemic
period before reperfusion, was found to reduce or at least
delay the ultimate size of the infarct and was associated
with the preservation of adenosine triphosphate and creatine
phosphate levels within the ischemic area.
Clinical implications. Reperfusion, either by throm-
bolytic therapy or coronary angioplasty, or both, is increas-
ingly employed in the treatment of acute myocardial in-
farction (4). The majority of patients who survive the initial
phase of acute myocardial infarction can receive thrombo-
lytic therapy, by either the intravenous or the intracoronary
route, within a few hours of the onset of symptoms. Un-
fortunately, the reocclusion rate after successful recanali-
zation ranges from 15 to 35% (10-12). The extrapolation
of experimental data to the human situation requires caution;
in particular, a heart rate at rest of 150 beats/min during
acute myocardial infarction is uncommon in humans. Also,
it is unlikely that maneuvers aimed at reducing infarct size
could be initiated within 1 hour of clinical symptoms of
acute myocardial infarction. However, these experiments
suggest that if verapamil is delivered to the myocardium
before reperfusion, it might delay cell death should reoc-
elusion occur and provide time for the reinstitution of throm-
bolytic therapy or for proceeding with mechanical means
of restoring myocardial perfusion.
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